Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal StudyPRNewsWire • 06/25/24
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024PRNewsWire • 06/10/24
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/06/24
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024PRNewsWire • 05/08/24
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154PRNewsWire • 05/01/24
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityPRNewsWire • 04/11/24
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisPRNewsWire • 03/28/24
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154PRNewsWire • 02/06/24
Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsPRNewsWire • 02/02/24
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaPRNewsWire • 01/18/24
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023PRNewsWire • 11/13/23
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023PRNewsWire • 11/08/23
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionPRNewsWire • 10/26/23